Metabolic Drugs for Cancer Handbook: The Detailed Exploration of Drug Approaches to Treat Cancers an

Cancer is fundamentally a disease of uncontrolled growth, and at the core of this relentless expansion lies a profound reprogramming of cellular metabolism. Tumor cells do not simply grow faster-they consume, redirect, and exploit nutrients in ways that fundamentally differ from normal tissues. This metabolic rewiring fuels rapid proliferation, sustains survival under stress, supports invasion and metastasis, and enables tumors to resist conventional therapeutics. As a result, cancer metabolism has emerged not only as a hallmark of malignancy but also as a powerful therapeutic frontier. The Metabolic Drugs for Cancer Handbook explores this frontier in depth, offering a detailed and comprehensive examination of drug strategies designed to disrupt cancer cell energy networks. These metabolic drugs aim to cut off the critical fuel lines-glucose, glutamine, lipids, and other vital substrates-that tumors depend on. By doing so, they target vulnerabilities unique to malignant cells while sparing normal tissues that retain metabolic flexibility. This handbook is built on the understanding that cancer cells are metabolically addicted. Many tumors exhibit heightened glycolysis even in the presence of oxygen, a phenomenon known as the Warburg effect. Others show profound dependence on amino acids such as glutamine, serine, or methionine, or rely heavily on fatty acid oxidation and lipid synthesis to maintain membrane production and redox balance. Targeting these addictions has led to an expanding class of metabolism-focused therapies, including glycolysis inhibitors, mitochondrial disruptors, glutaminase blockers, serine/glycine pathway inhibitors, and drugs targeting lipid metabolism and cholesterol homeostasis. However, targeting cancer metabolism requires more than blocking a single pathway. Tumors are metabolically adaptable; when one route is obstructed, they can activate compensatory mechanisms to secure alternative fuel sources. This handbook therefore emphasizes multi-target and combination strategies, showing how metabolic interventions can be paired with chemotherapy, radiotherapy, targeted therapy, and immunotherapy to create synergistic effects. By integrating metabolic drugs with standard oncology care, clinicians can amplify therapeutic impact, overcome resistance mechanisms, and achieve deeper, more durable responses.